Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges

Author: Peter Irving

$140.00

0 Units in Stock

Add to Cart:

 
  • ISBN: 9781444334548
  • Author: Peter Irving
  • Publ Date: 2011-11-11
  • Edition: 2
  • Pages: 294
  • Imprint: BLACKWELL *#
  • Status: ACT
  • ID - 13901

Table of Contents :

List of Contributors.
Preface.
Part 1: Genes and Phenotype in IBD.
1 Which will take us further in IBD study of codingvariation or epigenetics? (Miles Parkes).
2 IBD in different ethnic groups: same or different? (RupertW.L. Leong, Dorothy K.L. Chow and Christian P. Selinger).
Part 2: Bugs and IBD good, bad orindifferent?
3 How does the risk of infection influence management of IBDaround the world? (Kiran K. Peddi and Ian CraigLawrance).
4 Travelling with IBD (Ing Shian Soon and GilaadKaplan).
5 What to do about hepatitis B and hepatitis C in patients withIBD (Morven Cunningham and Graham R. Foster).
6 CMV in IBD passenger or pathogen? (Ahmed Kandiel& Bret Lashner).
7 Clostridium difficile in IBD: Impact, Prevention and Treatment(Ashwin N. Ananthakrishnan and David G. Binion).
8 Pre- and synbiotics: placebo or panacea (James O.Lindsay).
9 Worms light at the end of their burrow? (John Leungand Joel V. Weinstock).
10 Do we really need to vaccinate all patients with IBD?(Gauree Gupta and Gil Y. Melmed).
Part 3: Investigating IBD.
11 Biomarkers in IBD: myth or marvel? (Richard B. Gearry,Andrew S. Day).
12 Radiation exposure in IBD: how do we minimize the dangers?(Owen J O'Connor, Alan N. Desmond, Fergus Shanahan and MichaelM. Maher).
13 Surveillance colonoscopy in UC what s the bestway to do it? (Matt Rutter).
Part 4: Medical therapy.
5-ASA.
14 New 5ASAs: a tiny step or giant stride forward? (L. CampbellLevy).
15 Do 5ASAs prevent cancer? (Richard Logan and VenkataramanSubramanian).
16 Why do we still use 5-ASAs in Crohns disease? (StephenHanauer, Henit Yanai, Emma Calabrese).
Steroids.
17 Steroids in Crohn's disease: do the benefits outweigh thedangers? (A. Hillary Steinhart).
Immunomodulators.
18 Thioguanine nucleotide measurement: Non-adherent, shunter,under-dosed or resistant? (Miles Sparrow).
19 Thiopurines and the sun: what should be done? (Conal M.Perrett, Jane M. McGregor, Catherine A. Harwood).
20 Do thiopurines worsen risk and prognosis of cervicalneoplasia? (Jeremy D. Sanderson and Melissa A. Smith).
21 Optimising use of methotrexate (Anna Foley and Peter R.Gibson).
22 Which calcineurin inhibitor and when? (A. BarneyHawthorne).
Biologics.
23 Are all anti-TNF agents the same? (Jennifer L.Jones).
24 One drug or two: Do patients on biologics need concurrentimmunomodulation? (Glen A. Doherty and Adam S.Cheifetz).
25 How do we identify patients needing early aggressive therapyand what should we use? (Marc Ferrante and SeverineVermeire).
26 What is the role of biologics in UC? (Joanna K. Law andBrian Bressler).
27 What can we do with Crohn's patients refractory to antiTNFtherapy? (David T. Rubin).
28 Which EIMs respond to biologics? (Tina A. Mehta and CSProbert).
29 Use and abuse of biologics in pregnancy (Marla C.Dubinsky).
30 Is anti-TNF therapy safe to use in people with a history ofmalignancy? (Mark Lust and Simon Travis).
31 What and how should we tell patients about the risks ofimmunomodulators and biologics? (Corey A Siegel).
32 When, how and in whom should we stop biologics? (EdouardLouis, Jacques Belaiche, Catherine Reenaers).
Part 5: Other treatments.
33 Avoiding drug interactions (Tim Elliott and Peter M.Irving).
34 Is there still a role for ursodeoxycholic acid treatment inpatients with inflammatory bowel disease associated with primarysclerosing cholangitis? (Emmanouil Sinakos & KeithLindor).
35 Stem cell transplantation for Crohn's: what's therisk-benefit ratio? (Venkataraman Subramanian and Christopher JHawkey).
36 Complementary Therapy: Is There a Needle in the Haystack?(Shane M. Devlin).
Part 6: Surgical Dilemmas in IBD.
37 Optimising IBD patients for surgery and recovery (JonathanWilson and Alastair Windsor).
38 Is surgery the best initial treatment for limited ileocaecalCrohn's disease? (Tom Oresland).
39 Laparoscopic or open surgery for IBD? (Donna Appleton andMichael Hershman).
40 Perianal Crohn's disease optimal management (DavidA. Schwartz and Norman R. Clark III).
41 Does anti-TNF therapy increase the risk of Complications ofsurgery? (Ming Valerie Lin, Wojciech Blonski and Gary R.Lichtenstein).
42 Pouches for Indeterminate Colitis and Crohn's Disease: ActNow, Pay Later? (Phillip Fleshner).
43 Dealing with pouchitis (Bo Shen and SimonMcLaughlin).
Part 7: Unsolved issues in IBD.
44 Mucosal healing in IBD does it matter? (GeertD'Haens).
45 Vitamin D in IBD: from genetics to bone health via cancer andimmunology (Helen M. Pappa and Richard J. Grand).
46 Got Milk? Medication Use and Nursing in Women with IBD(Sunanda Kane).
47 Does stress matter? (Robert Maunder).
48 IBS is common in IBD: fact or fallacy? (James Goodhand& David Rampton).
49 So where is all the cancer? (Judith E. Baars & C.Janneke van der Woude).
Part 8: Nutrition in IBD.
50 What should patients with IBD eat? (Emile Richman, KeithLeiper, Jonathan Rhodes).
51 Enteral Nutrition in Crohn's - Who for, When, How and WhichFormula? (R. Shamir and Ernest G. Seidman).
52 Optimizing treatment of iron deficiency anemia (HermannSchulze and Axel Dignass).
Part 9: Management process.
53 IBD Standards: will they enhance patient care? (Michael D.Kappelman).
54 Your treatment won t work if the patient doesn't takeit (Rob Horne).
55 Inflammatory Bowel Disease: What to tell your ED team(Louise Langmead).
56 Transitioning from pediatric to adult care (Elizabeth J.Hait and Laurie N. Fishman).
57 Medicolegal Pitfalls in Inflammatory Bowel Disease (IBD) Care(William J. Tremaine).

Description:

The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking. Each of the 57 evidence-based chapters contains clear learning points, addresses different topics, and provides sound guidance on subjects ranging from optimizing current management through to special management problems and novel treatments. This book is suitable for all medical professionals involved in the care of patients with IBD: established and trainee gastroenterologists, colorectal surgeons, pathologists, radiologists, specialist nurses, pharmacists, dieticians and counselors.

Review:


Bottom Line: Clinical Dilemmas inInflammatory Bowel Disease: New Challengestargets the IBD clinicianand is a practical, well-written, easy-to-use text that will beinvaluable to all involved in the care of IBD patients, includinggastroenterologists, nurses, colorectal surgeons, anddieticians. Trainee gastroenterologists will find this textuseful both in IBD management and as a source for IBD clinicalpresentations. I highly recommend this text for anyone who isengaged in the day-to-day clinical care of patients withIBD. (Gastroenterology, 1 December 2012)"This is a timely update and expanded second edition that examinesmany newer clinical dilemmas in IBD. The short chapters are easy toabsorb and key opinion leaders offer interesting insights. Itcertainly justifies replacing the previous edition." (Doody's, 24February 2012)


 

Estimated Delivery Times
In stock items despatched next working day
Out of stock items -locally sourced 2-5 days overseas 6-12 days
(if in stock at publisher)

Your IP Address is: 54.221.76.68
Copyright © 2003-2014 Medicalbooks Shopping Cart